Clinical Pharmacology. Pharmacodynamics the next step. Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand

Similar documents
Pharmacodynamic principles and the time course of immediate drug effects

1. Immediate 2. Delayed 3. Cumulative

Understand the physiological determinants of extent and rate of absorption

CLINICAL TRIAL SIMULATION & ANALYSIS

Volume of Distribution. Objectives. Volume of Distribution

Pharmacokinetics Overview

Biopharmaceutics Lecture-11 & 12. Pharmacokinetics of oral absorption

Clinical Pharmacology. Clinical Pharmacology = Disease Progress + Drug Action. Outline. Disease Progress and Drug Action

The Time Course of Placebo Response in Clinical Trials

Delayed Drug Effects. Distribution to Effect Site. Physiological Intermediate

Basic Concepts of TDM

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

Pharmacokinetics Applied to the Treatment of Asthma

Disease Progress. Clinical Pharmacology = Disease Progress + Drug Action. Outline. Parkinson s Disease. Interpretation of ELLDOPA

BASIC PHARMACOKINETICS

PHARMACOKINETICS OF DRUG ABSORPTION

Pharmacodynamics. Delayed Drug Effects. Delayed and Cumulative Effects

Concentration of drug [A]

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:

PHARMACODYNAMICS II. The total number of receptors, [R T ] = [R] + [AR] + [BR] (A = agonist, B = antagonist, R = receptors) = T. Antagonist present

PHAR 7633 Chapter 20 Non Compartmental Analysis

Pharmacology. Biomedical Sciences. Dynamics Kinetics Genetics. School of. Dr Lindsey Ferrie

Unit 1 Exploring and Understanding Data

Speed Accuracy Trade-Off

PHARMACODYNAMICS II QUANTITATIVE ASPECTS OF DRUGS. Ali Alhoshani, B.Pharm, Ph.D. Office: 2B 84

Implementing receptor theory in PK-PD modeling

Pharmacodynamics. Dr. Alia Shatanawi

Environmental Variability

Chapter 3 CORRELATION AND REGRESSION

Nonlinear Pharmacokinetics

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations

Receptor Occupancy Theory

Past Years Questions Chpater 6

PHA5128 Dose Optimization II Case Study I Spring 2013

Pharmacokinetics of drug infusions

Children are small adults and babies are young children

BIOPHARMACEUTICS and CLINICAL PHARMACY

Recording and Analysing Concentration- Response Curves. should be slightly higher, or at least within the range of the dissociation constant K D

Tutorial. & In case studies 1 and 2, we explore intravenous iv. & Then, we move on to extravascular dosing in case

MEASURES OF ASSOCIATION AND REGRESSION

PHA Final Exam Fall 2006

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

Pharmacodynamics Dr. Iman Lec. 2

Clinical Trials A Practical Guide to Design, Analysis, and Reporting

SCATTER PLOTS AND TREND LINES

Results & Statistics: Description and Correlation. I. Scales of Measurement A Review

The general Concepts of Pharmacokinetics

Biomath M263 Clinical Pharmacology

General Principles of Pharmacology and Toxicology

Models of Parent-Offspring Conflict Ethology and Behavioral Ecology

Numerical Integration of Bivariate Gaussian Distribution

Osnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,

Psychology of Perception Psychology 4165, Spring 2003 Laboratory 1 Weight Discrimination

1.4 - Linear Regression and MS Excel

Fitting a Single-Phase Model to the Post-Exercise Changes in Heart Rate and Oxygen Uptake

Lecturer: Rob van der Willigen 11/9/08

Lippincott Questions Pharmacology

Psychology of Perception Psychology 4165, Fall 2001 Laboratory 1 Weight Discrimination

Lecturer: Rob van der Willigen 11/9/08

DEFINITIONS. Pharmacokinetics. Pharmacodynamics. The process by which a drug is absorbed, distributed, metabolized and eliminated by the body

Reminders/Comments. Thanks for the quick feedback I ll try to put HW up on Saturday and I ll you

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

J. Biosci., Vol. 7, Number 2, March 1985, pp Printed in India.

You should know the T max for any substance that you use and for PAH ; T max = mg / min

Time to Lowest BIS after an Intravenous Bolus and an Adaptation of the Time-topeak-effect

PubH 7405: REGRESSION ANALYSIS

CHILD HEALTH AND DEVELOPMENT STUDY

Stewart Calculus: Early Transcendentals, 8th Edition

Biochemistry Department. Level 1 Lecture No : 3 Date : 1 / 10 / Enzymes kinetics

IAPT: Regression. Regression analyses

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Contents. What is item analysis in general? Psy 427 Cal State Northridge Andrew Ainsworth, PhD

General Principles of Pharmacology and Toxicology

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

Model-based quantification of the relationship between age and anti-migraine therapy

Life History of A Drug

Clozapine Case 6: Half-Life Jose de Leon, MD

10. LINEAR REGRESSION AND CORRELATION

Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products

Determination of the Diffusion Coefficient for Sucrose in Aqueous Solutions

January 25, Introduction to Pharmacology

Why Using pic50 Instead of IC50 Will Change Your Life

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

One-Compartment Open Model: Intravenous Bolus Administration:

Case Study in Placebo Modeling and Its Effect on Drug Development

Business Statistics Probability

Psychology of Perception Psychology 4165, Spring 2016 Laboratory 2: Perception of Loudness

Psychology of Perception PSYC Spring 2017 Laboratory 2: Perception of Loudness

Challenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products

PHARMACOKINETICS SMALL GROUP I:

General Principles of Pharmacology and Toxicology

Electromyography II Laboratory (Hand Dynamometer Transducer)

Cleveland State University Department of Electrical and Computer Engineering Control Systems Laboratory. Experiment #3

Preliminary Report on Simple Statistical Tests (t-tests and bivariate correlations)

BOOTSTRAPPING CONFIDENCE LEVELS FOR HYPOTHESES ABOUT QUADRATIC (U-SHAPED) REGRESSION MODELS

Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics

PKPD. Workshop. Warfarin Data. What does this mean? Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand

Regression. Lelys Bravo de Guenni. April 24th, 2015

Pharmacokinetics PCTH 325. Dr. Shabbits September 12, C t = C 0 e -kt. Learning Objectives

Imperfect, Unlimited-Capacity, Parallel Search Yields Large Set-Size Effects. John Palmer and Jennifer McLean. University of Washington.

Transcription:

1 Pharmacodynamic Principles and the Course of Immediate Drug s Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand The time course of drug action combines the principles of pharmacokinetics and pharmacodynamics. Pharmacokinetics describes the time course of concentration while pharmacodynamics describes how effects change with concentration. There are 3 ways to think of the time course of effects: Drug effects are immediately related to observed drug concentration (e.g. in plasma) Drug effects are delayed in relation to observed drug concentration Drug effects are determined by the cumulative action of the drug This presentation outlines the basic principles of the concentration-effect relationship (pharmacodynamics) and illustrates the application of pharmacokinetics and pharmacodynamics to predict the time course of immediate drug effects. 2 Pharmacodynamics the next step 3 Clinical Pharmacology Pharmacokinetics Pharmacodynamics CL V C Dose entration Clinical pharmacology describes the effects of drugs in humans. One way to think about the scope of clinical pharmacology is to understand the factors linking dose to effect. Drug concentration is not as easily observable as doses and effects. It is believed to be the linking factor that explains the time course of effects after a drug dose. The science linking dose and concentration is pharmacokinetics. The two main pharmacokinetic properties of a drug are clearance (CL) and volume of distribution (V). The science linking concentration and effect is pharmacodynamics. The two main pharmacodynamic properties of a drug are the maximum effect () and the concentration producing % of the maximum effect (C). The C is also known as EC but C is preferred to make it clearer this is a concentration and not an effect scaled parameter.

4 Objectives Learn the model of drug action Understand why log concentration models are misleading Be able to describe the time course of drug action after a bolus dose Appreciate the determinants of the duration of drug action 5 T 1/2 =? 16 8 8 16 4 24 2 32 4 5 48 2.5 56 1.25 64.625 What is the half-life? 6 T 1/2 =8 C=? 16 94 8 8 89 16 4 8 24 2 67 32 4 5 33 48 2.5 2 56 1.25 11 64.625 5.9 The half-life was 8 time units. Can you guess the C of the drug? You will have to make an assumption about the maximum possible effect of the drug ()

7 9 8 7 6 4 3 2 and Based on the law of mass action principle the binding of a drug to a receptor should follow a hyperbolic curve (as shown here). If it is assumed that the effect is directly proportional to the binding then the C will be the same as the Kd. The Kd is the equilibrium binding constant. It is the concentration of unbound drug at which % of binding sites are occupied. 2 3 4 6 7 8 9 C Notice that can never be directly observed. It is the asymptotic effect of the drug at infinite concentration. Even times the C only reaches 9% of. 8 9 Log Transformation This figure shows the identical values for concentration and effect as that shown on the previous figure. The only change is in the X-axis of the graph to a logarithmic scale. 8 7 6 4 3 2.1.1 1 The log transformation changes the shape of the curve so that it now looks S-shaped (sigmoid) but this is not a sign of a sigmoid model (see later). The transformed X-axis allows a wider range of concentrations to be plotted and it can be seen that at very high concentrations the effect approaches. C The portion of the curve between 2 and 8% of is approximately a straight line. This almost linear relationship was helpful before the days of computers because the slope could be described by simple calculations. Older textbooks commonly refer to log-dose response curves. It is important to appreciate that there is no underlying biological or physical reason to think that drug effects are related more closely to the log of concentration than untransformed concentrations. A problem arises from thinking that effects are related to the log of concentration when the concentration is known to be zero: E=a+b*log(C) At zero concentration is obvious that the effect must be zero but the log of zero is mathematically undefined and so the effect is also undefined. The log concentration model also does not recognize that effects will approach a maximum which is always the case for biological systems.

9 E E max C Model E is the drug effect is the conc at the receptor is the maximum drug effect C is the conc at % of The model is the most fundamental description of the concentration effect relationship. It has strong theoretical support from the physicochemical principles governing binding of drug to a receptor (the law of mass action). All biological responses must reach a maximum and this is an important prediction of the model. When concentrations are low in relation to the C then the concentration effect relationship can be approximated by a straight line (the linear pharmacodynamic model): E=Slope* Model Predictions E max E C = C =1.25 2 C 2 1 2 67 3 75 4 8 C 5 83 8 6 86 7 88 8 89 9 9 91 99 99 The C is the concentration producing % of There are two other useful concentrations to remember: C2 the concentration at 2% of. It is ¼ of C C8 the concentration at 8% of. It is 4 times the C This means the model predicts a 16 times change in concentration is needed to change the effect from 2 to 8% of. Many drugs seem to have a steeper relationship of concentration and effect so that a smaller change is required. These steeper relationships can be described by the sigmoid model. 11 Hill Sigmoid Model E max E C Hill Hill E is the drug effect is the conc at the receptor is the maximum drug effect C is the conc at % of Hill determines steepness In 19, the physiologist Hill was investigating the shape of the oxygen haemoglobin saturation relationship. He noted it was steeper than the simple binding predictions of the model. By trial and error he found that adding an exponential parameter to the concentration and C terms in the model the shape of the relationship could be made steeper. This extra parameter is known as the Hill coefficient. Subsequently the molecular biologist Perutz won a Nobel prize for describing the structure of haemoglobin which incorporates 4 binding sites for oxygen. The binding of each oxygen atom affects the other binding sites and causes the steep oxygen-haemoglobin binding curve. Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, et al. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol. 28;22(6):633-48.

12 Sigmoid Model in units of C Hill =.5 Hill = 1 Hill = 2 Hill = 5 The sigmoid model is shown with 4 different values for the Hill coefficient. When Hill=1 the curve is the same as the model. When Hill is greater than 1 the curve is steeper and when it is less than 1 it is shallower than the model. When Hill=2 it only takes as 4 fold change in concentration to go from C2 to C8. When Hill is very large (>) the concentration effect relationship is almost like an on-off switch. The effect turns on at a threshold concentration close to the C. I doubt if there are any convincing examples of this kind of threshold concentration response. Figure modified from: Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, et al. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol. 28;22(6):633-48. 13 Peak Flow Change % 9 8 7 6 4 3 2 Theophylline 2 3 4 6 7 8 9 Theophylline is used to treat severe asthma. It is a bronchodilator. Airway constriction slows the peak flow rate of air from the lungs. Theophylline can increase the peak flow rate and as an C of about mg/l. In the example shown here the maximum effect of theophylline () is to increase peak flow by % above the baseline peak flow. C mg/l 14 Course of The following slides illustrate the time course of drug effect and offer answers to the questions on this slide. How long does the drug effect last? Is there a half-life for effect? What is the relevance of C?

15 Peak= x C 9 9 8 8 7 7 6 6 4 4 3 3 2 2 12 24 36 48 This is the first of three figures showing how the time course of immediate drug effect depends upon the initial concentration as well as the pharmacokinetics of the drug. This figure shows the time course of concentration (blue line) after a bolus dose at time zero. The half-life is about 9 hours (similar to theophylline). The initial concentration is times the C for theophylline and this produces an initial effect of 9% of (red line). After one half-life the concentration is halved but the effect has changed by less than %. As concentration falls the effect disappears more quickly. 16 9 8 7 6 5 4 Peak = C 45 4 35 3 15 2 1 5 12 24 36 48 3 25 2 If a smaller dose is given so that the initial concentration is the same as the C then the initial effect will only be % of. At these lower concentrations the time course of effect is almost parallel to the time course of concentration. 17 Peak = x C 9 9 8 8 7 7 6 6 4 4 3 3 2 2 12 24 36 48 When a very big dose is given so that the initial concentration is times the C then the initial effect is close to % of. The effect changes very little despite big changes in drug concentration. After more than 5 halflives when nearly all the initial dose will have been eliminated from the body the effect is still 7% of. This figure is important because it shows how drugs which have short half-lives can have big effects even if the dosing interval is many half-lives. This is quite common for receptor antagonists e.g. beta-blockers and angiotensin-converting enzyme inhibitors.

18 Flat» > C 8 Linear» C 8 > > C 2 Exponential» < C 2 Course of Three Regions 9 8 7 6 4 3 2 12 24 36 48 6 72 9 8 7 6 4 3 2 In summary the time course of effect can be described by three regions by considering if concentrations are above the C8 or below the C2. When concentrations are very high (greater than C8) the curve is almost flat. There is little change in effect despite big changes in concentration. When concentrations are very low (less than C2) the curve is almost exponential. The time course of concentration and effect are almost parallel to one another. This is the only time it makes sense to describe the effect as having a half-life. In between the C2 and C8 the time course of loss of drug effect is almost a straight line. 19 9 8 7 6 4 3 2 Duration of Response One Half Life One Half Life One Half Life 12 24 36 48 6 72 9 8 7 6 4 3 2 This looks like a complicated figure but it illustrates a very simple principle -- If the dose of a drug is doubled then the duration of response will increase by one half-life. The duration of response means the time that the drug effect is above a predefined critical value e.g. the time above % of. With a low dose (blue lines) the duration of effect is about 2 hours. At 2 h the concentration is equal to mg/l (the C). Doubling the dose (red lines) prolongs the duration of effect to nearly 3 h (one half-life). At 3 h the concentration is equal once again to mg/l with the same level of effect () that was used to mark the end of the response for the lower dose. The increase in duration of response from doubling the dose is independent of the size of effect that is chosen to mark the end of the response. 2 Applications Prediction of the target concentration from the target effect The most important application is to translate the desired clinical effect (the target effect) into a target concentration. Re-arrangement of the equation leads to a prediction of the target concentration to reach the target effect. C E max

21 Applications Selection of an appropriate dosing interval depends on more than the half-life the target concentration and it s relation to the C must be considered too. e.g. half life of hours but effective daily dosing» Beta blockers» Ace Inhibitors» Prednisone/prednisolone Selection of a dosing interval so sustain a desired level of effect has to take into account the time course of effect. In the simplest case this depends on both the half-life and the C. Many drugs have short half-lives (hours) yet are effective with once a day dosing. This is usually because concentrations are above the C for most of the day. 22 Applications entration effect curves are nonlinear ( model) effects do not increase in direct proportion to the dose. Doubling the dose usually does not lead to doubling of effect Doubling the dose will increase the duration of effect by 1 half-life 23 The way to go!